# Teladoc Health Stock Pops - Here's Why

- URL: https://theranews.net/blog/2026-03-11-teladoc-health-stock-pops-heres-why-1c174c/
- Published: 2026-03-11
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: benzinga
- Original report: https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51160654/teladoc-health-stock-pops-heres-why
- Topics: mental-health
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> Teladoc Health Inc. (NYSE:TDOC) shares are up on Tuesday.TDOC Reported Stronger-Than-Expected Quarterly ResultsIn February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents.Additionally, sales increased to $642.27 million, surpassin

---
Teladoc Health shares were up on Tuesday following stronger-than-expected quarterly results. In February, Teladoc Health reported a quarterly loss of 14 cents per share, outperforming the consensus loss of 18 cents. Sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%.

## Forward Guidance and Analyst Perspective

Teladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million. For fiscal 2026, the company sees a loss of 70 cents to $1.10 with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion respectively.

## Mixed Analyst Sentiment

Deutsche Bank upgraded TDOC from Hold to Buy, citing a compelling valuation and a potential exit scenario, with a price forecast of $11. BTIG remained cautious, noting that "given a difficult macro environment, a seemingly saturated tele-health market, and a highly competitive behavioral health market," it maintains a Neutral rating. Oppenheimer reiterated Outperform and lowered its price target from $12 to $7. Citigroup and BMO Capital both lowered targets as well—from $9 to $6 and from $8 to $5, respectively.

## Technical Performance

The stock was trading 21.8% above its 20-day simple moving average but 12.5% below its 100-day SMA, indicating short-term strength while struggling longer-term. Over the past 12 months, shares have decreased 40.65%. The RSI at 52.22 suggests neutral territory, while MACD at -0.1341 above its signal line at -0.2551 indicates bullish momentum. Teladoc Health shares were up 5.57% at $5.59 at the time of publication on Tuesday.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51160654/teladoc-health-stock-pops-heres-why](https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/03/51160654/teladoc-health-stock-pops-heres-why)*